• Assess the underlying and overlapping inflammatory pathways in hidradenitis suppurativa (HS) and rheumatic diseases.
• Recognize the impact of HS on disease-specific and patient-reported outcomes in patients with and without rheumatic diseases.
• Evaluate new and emerging treatment options for HS based on mechanisms of action, efficacy and safety data, and patient eligibility.
• Apply current evidence, patient factors, and collaborative strategies to make individualized treatment decisions for rheumatology patients with HS.

• Presentation and Impact of HS on Rheumatology Patients
• Unique and Shared Immunological Pathways of HS with Rheumatic Diseases
• Validated Tools to Assess Activity, Severity, and Treatment Response of HS
• New and Emerging Targeted Therapies for Moderate to Severe HS
• Strategies for Personalized Collaborative Care for Patients with Skin and Joint Disease

• This activity has been approved for AMA PRA Category 1 Credit(s)™ and MOC Credit.
  See the final CE activity announcement for specific details.

There is no commercial support for this accredited activity.